164 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint http://www.zacks.com/stock/news/291238/foreign-stock-roundup-rdsa-azn-impress-nvo-baba-disappoint?cid=CS-ZC-FT-291238 Feb 05, 2018 - Losses on Wall Street and falling bond yields weighed on global markets this week.
3 Top Obesity-Drug Stocks to Consider Buying Now https://www.fool.com/investing/2018/02/03/3-top-obesity-drug-stocks-to-consider-buying-now.aspx?source=iedfolrf0000001 Feb 03, 2018 - Most obesity drugs haven't been huge successes. But these stocks just might be.
Novo Nordisk's (NVO) CEO Lars Fruergaard Jørgensen on Q4 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4142435-novo-nordisks-nvo-ceo-lars-fruergaard-jorgensen-q4-2017-results-earnings-call-transcript?source=feed_sector_healthcare Feb 01, 2018 - Novo Nordisk (NYSE:NVO) Q4 2017 Earnings Conference Call February 01, 2018 07:00 AM ET Executives Lars Fruergaard Jørgensen - CEO Jesper Brandgaard - CFO Mads Krogsgaard Thomsen - CSO Lars Green - EVP
Allergan (AGN) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/291003/allergan-agn-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-291003 Feb 01, 2018 - While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat http://www.zacks.com/stock/news/290912/novo-nordisk-nvo-misses-q4-earnings-estimates-sales-beat?cid=CS-ZC-FT-290912 Feb 01, 2018 - Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.
Why Novo Nordisk (NVO) Might Surprise This Earnings Season http://www.zacks.com/stock/news/290556/why-novo-nordisk-nvo-might-surprise-this-earnings-season?cid=CS-ZC-FT-290556 Jan 30, 2018 - Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings? http://www.zacks.com/stock/news/290595/can-merck-mrk-deliver-a-positive-surprise-in-q4-earnings?cid=CS-ZC-FT-290595 Jan 30, 2018 - Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.
Company News For Jan 30, 2018 http://www.zacks.com/stock/news/290592/company-news-for-jan-30-2018?cid=CS-ZC--290592 Jan 30, 2018 - Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO
Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B http://www.zacks.com/stock/news/290580/sanofi-on-a-buyout-spree-this-month-to-buy-ablynx-for-%2448b?cid=CS-ZC-FT-290580 Jan 30, 2018 - Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call http://www.zacks.com/stock/news/290323/abbvie-abbv-soars-on-q4-results-key-takeaways-from-the-earnings-call?cid=CS-ZC-FT-290323 Jan 29, 2018 - With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.

Pages: 1...345678910111213...17

<<<Page 8>